Showing results (21-30 of 86) with videos related to

Sort By:
Pageof 9
Molecular Cancer Therapeutics|October 8, 2011
Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotypeMichael F Emmons, Anthony W Gebhard, Rajesh R Nair, et al.
European Journal of Haematology|January 21, 2015
An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myelomaTaiga Nishihori, Rachid Baz, Kenneth Shain, et al.
Cancer Research|December 7, 2013
A preclinical assay for chemosensitivity in multiple myelomaZayar P Khin, Maria L C Ribeiro, Timothy Jacobson, et al.
Haematologica|September 12, 2006
The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myelomaRony M Abou-Jawde, Rachid Baz, Esteban Walker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2012
Stemness of B-cell progenitors in multiple myeloma bone marrowKelly Boucher, Nancy Parquet, Raymond Widen, et al.
Leukemia Research|August 31, 2007
Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemiaCristina P Rodriguez, Rachid Baz, Rony Abou Jawde, et al.
Oncotargets and Therapy|September 13, 2022
Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple MyelomaSyeda Saba Kareem, Neena Viswanathan, Solmaz Sahebjam, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 5, 2011
Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experienceDaniel Lebovic, Ling Zhang, Melissa Alsina, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 9, 2022
The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With CytopeniaJinming Song, Hailing Zhang, Ning Dong, et al.
Blood|May 10, 2017
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myelomaThomas Martin, Rachid Baz, Don M Benson, et al.
Pageof 9